Introduction
In the last few years, accumulating evidence has indicated that numerous long noncoding RNAs (lncRNAs) are abnormally expressed in gastric cancer (GC) and are associated with the survival of GC patients. GC is the fourth most diagnosed tumor type and the third most common origin of tumor-related death all over the world. 114, 115 Although the incidence and mortality of GC are declining, .24,590 individuals are diagnosed with GC per year, of which 10,720 die from GC in the USA. 116 Although diagnosis and treatment strategies have been improved, the number of surviving cases remains low, since diagnosis submit your manuscript | www.dovepress.com
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gao et al often occurs in the late stages. 116, 117 Thus, the molecular characteristics about the carcinogenesis of GC and the recognition of new biomarkers for GC are urgently needed.
lncRNA is a new type of noncoding RNA that has a length of .200 nucleotides (nt) and lacks important open reading frameworks and can be divided into five main categories (sense, antisense, bidirectional, intronic and intergenic). 118 Abundant evidence has demonstrated that lncRNAs play significant regulatory roles in tumor biology via various mechanisms affecting transcriptional and posttranscriptional levels. [118] [119] [120] Currently, for both cell behavior and clinicopathological factors, significant advances with respect to lncRNA effects on GC have been discovered. 121 On account of the obvious expression differences between normal and malignant tissues as well as causal roles of lncRNAs in cancer development, lncRNAs are now attracting increasing attention, which has led to numerous investigations of the correlation between lncRNA states and clinical results in GC. Nevertheless, most of these studies were performed with small samples, and there were inconsistently observed connections. Consequently, we conducted a meta-analysis to determine the accurate role of lncRNAs in the prognosis of GC patients, which possibly supplied us with new insights into the clinical value of combined detection in forecasting prognostic results and determining promising biomarkers in GC treatment strategies.
Methods
literature search strategy
We basically performed a systematic selection of papers published in English from four databases (PubMed, Web of Science, Embase and Cochrane Database of Systematic Reviews). A comprehensive search was conducted using the subject term: lncRNA and gastric cancer. Two authors (Song Gao and Zhi-Ying Zhao) checked the titles and abstracts of the retrieved papers, and Yue Zhang reevaluated uncertain data. Figure 1 shows the flow diagram of the literature search and selection.
inclusion criteria
We set up inclusion criteria for qualified papers, which were analyzed using our full-text assessment: 1) articles 
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Prognostic value of lncrnas in gastric cancer concerning the pertinence between lncRNA level in cancer tissues and prognosis of GC patients; 2) the survival results were estimated using overall survival (OS) and 3) full-text papers published in English.
exclusion criteria
Articles that did not meet the abovementioned inclusion criteria, reviews, letters and laboratory studies without raw data were excluded. Articles of non-dichotomous lncRNA expression levels and frequency of studies evaluating prognostic value of lncRNAs equal to 1 were also excluded. If more than one paper had been published on the identical study cohort, only the most well-rounded investigation was selected for this research. In addition, if both of the univariate and multivariate outcomes were covered, only the latter were chosen, since they were adjusted for confounding factors. research frequency Table 1 gives the frequency of investigations reporting prognosis of GC patients, which included the lncRNA name, frequency of researched lncRNA and reference.
Data extraction
The survival data were recovered from qualified articles independently by two authors (Song Gao and Zhi-Ying Zhao). Data extracted from them are as follows: researched lncRNA, -isoform 2  1  85  agaP2-as1  1  5  hOTTiP  3  50-52  PanDar  2  86, 87  aK023391  1  6  hOXa-as2  1  53  PcaT1  1  88  aK093735  1  7  hXa11-as  1  54  PVT1  2  89, 90  aK123072  1  8  KrTi8P55  1  55  rP11-119F7.4  1  91  anril  2  9, 10  leT  1  56  rP11-120K18.2  1  1  aTB  1  11  linc00052  1  57  rP11-389g6.3  1  1  Bancr  1  12  linc00152  1  58  rP11-499F3.2  1  1  Bc005927  1  13  linc00628  1  59  rP11-789c1.1  1  92  Bc032469  1  14  linc00668  1  60  rPlPOP2  1  29  Bc041951  1  15  linc00673  2  61, 62  slc26a4  1  29  Bcar4  1  16  linc00675  1  63  sMiM10l2a  1  29  casc2  1  17  linc00982  1  64  sMiM10l2B  1  29  casc15  2  18, 19  linc01018  1  65  snhg1  1  93  ccaT1  1  20  linc01234  1  66  snhg6  1  94  ccaT2  2  21, 22  linc01296  1  67  snhg12  1  95  chrDl1  1  23  linc-rOr  1  68  snOrD116-4  1 122 The random-effect model was used in the whole article because different histological type (frozen, formalin-fixed paraffin-embedded or undefined) from GC patients at different neoplasm staging, cutoff value and lncRNA detected method was used in the single study. The HR was considered significant if its P-value was ,0.05 and 95% CI did not contain the value 1. Furthermore, the lncRNA was considered as a strong biomarker of prognosis, if its HR was .2. The Begg's funnel plot was used to estimate publication bias, and a two-tailed P-value ,0.05 was considered as significant. The sensitivity analysis was performed to examine how sensitive the merged HR was if the single study was removed, and if the point of evaluation was outside the 95% CI after it was removed from the whole analysis, a single research was considered as excessive influence. Table 3 gives the basic information of the merged metaanalysis for researched lncRNAs.
Results
Meta-analysis
aFaP1 antisense rna 1 (aFaP1-as1), cDKn2B antisense rna 1 (anril), cancer susceptibility 15 (casc15), colon cancer-associated transcript 2 (ccaT2), gastric adenocarcinoma associated, positive cD44 regulator, long intergenic noncoding rna (gaPlinc) and h19, imprinted maternally expressed transcript (h19) demonstrated significantly prognostic value Two articles 3, 4 reported the relationship between high AFAP1-AS1 expression and OS, indicating that GC patients with its high expression had significantly worse OS than those with its low expression (HR=2.47, 95% CI=1.41-4.30, P,0.01). Abbreviations: AFAP1-AS1, AFAP1 antisense RNA 1; ANRIL, CDKN2B antisense RNA 1; Both, frozen and formalin-fixed paraffin-embedded tissues; CASC15, cancer susceptibility 15; CCAT2, colon cancer associated transcript 2;
FFPE, formalin-fixed paraffin-embedded; GAPLINC, gastric adenocarcinoma associated, positive CD44 regulator, long intergenic noncoding RNA; GEO, Gene Expression Omnibus; H19, H19, imprinted maternally expressed transcript; hOTair, hOX transcript antisense rna; hOTTiP, hOXa distal transcript antisense rna; hr (h/l), hazard ratios of high expression versus low expression of lncrnas; hr (l/h), hazard ratios of low expression versus high expression of lncrnas; KM, Kaplan-Meier plotter; linc00673, long intergenic non-protein coding rna 673; lncrna, long noncoding rna; MalaT1, metastasis-associated lung adenocarcinoma transcript 1; Meg3, maternally expressed 3; Os, overall survival; PanDar, promoter of cDKn1a antisense Dna damage activated rna; PVT1, Pvt1 oncogene; qrT-Pcr, quantitative real-time polymerase chain reaction; r, retrospective; rT-qPcr, reverse transcription quantitative real-time polymerase chain reaction; Sox2ot, SOX2 overlapping transcript; SPRY4-IT1, SPRY4 intronic transcript 1; TCGA, The Cancer Genome Atlas; UCA1, urothelial cancer associated 1; XIST, X inactive specific transcript; ZEB1-AS1, ZeB1 antisense rna 1; ZFas1, ZnFX1 antisense rna 1.
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gao et al Two researches 9, 10 covered the connections between high ANRIL expression and OS, suggesting that GC patients with its high expression had significantly poorer OS than those with its low expression (HR=1.68, 95% CI=1.16-2.43, P,0.01).
Two investigations 18, 19 analyzed the associations between high CASC15 expression and OS, showing that GC patients with its high expression had significantly shorter OS than those with its low expression (HR=1.99, 95% CI=1.21-3.28, P,0.01).
Two studies 21, 22 focused on the correlation between high CCAT2 expression and OS, manifesting that GC patients with its high expression had significantly worse OS than those with its low expression (HR=2.17, 95% CI=1.53-3.09, P,0.01).
Two papers 32, 33 paid attention to the pertinence between high GAPLINC expression and OS, demonstrating that GC patients with its high expression had significantly poorer OS than those with its low expression (HR=1.49, 95% CI=1.18-1.89, P,0.01).
Four literature 29, [36] [37] [38] described the relativity between high H19 expression and OS, proving that GC patients with its high expression had significantly shorter OS than those with its low expression (HR=1.51, 95% CI=1.05-2.17, P=0.03; Figure 2 ).
hOX transcript antisense rna (hOTair) demonstrated significantly prognostic value
Nine essays [41] [42] [43] [44] [45] [46] [47] [48] [49] discussed the relation between high HOTAIR expression and OS, illuminating that GC patients with its high expression had significantly worse OS than those with its low expression (HR=1.93, 95% CI=1.53-2.43, P,0.01; Figure 3 ).
Publication bias
The Begg's funnel plot was used to estimate publication bias, and its P-value was 0.20, so there was no significant publication bias in the pooled analysis of OS about high HOTAIR expression (Figure 4 ).
sensitivity analysis
The sensitivity analysis was performed to examine how sensitive the merged HR was if the single study was removed. Abbreviations: aFaP1-as1, aFaP1 antisense rna 1; anril, cDKn2B antisense rna 1; casc15, cancer susceptibility 15; ccaT2, colon cancer associated transcript 2; gaPlinc, gastric adenocarcinoma associated, positive cD44 regulator, long intergenic noncoding rna; gc, gastric cancer; h19, h19, imprinted maternally expressed transcript; hOTair, hOX transcript antisense rna; hOTTiP, hOXa distal transcript antisense rna; linc00673, long intergenic non-protein coding rna 673; lncrna, long noncoding rna; MalaT1, metastasis-associated lung adenocarcinoma transcript 1; Meg3, maternally expressed 3; PanDar, promoter of cDKn1a antisense Dna damage activated rna; PVT1, Pvt1 oncogene; sox2ot, sOX2 overlapping transcript; sPrY4-iT1, sPrY4 intronic transcript 1; Uca1, urothelial cancer associated 1; XIST, X inactive specific transcript; ZEB1-AS1, ZEB1 antisense RNA 1; ZFAS1, ZNFX1 antisense RNA 1.
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Prognostic value of lncrnas in gastric cancer
After this process, no individual study significantly affected the combined HR with 95% CI ( Figure 5 ).
hOXa distal transcript antisense rna (hOTTiP), long intergenic non-protein coding rna 673 (linc00673), metastasis-associated lung adenocarcinoma transcript 1 (MalaT1), maternally expressed 3 (Meg3), promoter of cDKn1a antisense Dna damage activated rna (PanDar) and Pvt1 oncogene (PVT1) demonstrated significantly prognostic value
The details are shown in Table 3 and Figure 6 .
sOX2 overlapping transcript (sox2ot), urothelial cancer-associated 1 (UCA1), X inactive specific transcript (XisT), ZeB1 antisense rna 1 (ZeB1-as1) and ZnFX1 antisense rna 1 (ZFas1) demonstrated significantly prognostic value
The details are shown in Table 3 and Figure 7 .
Discussion current situation
So far, the clinical treatment of GC remains limited. In the past score years, there has been little progress in both traditional Figure 2 Forest plot of pooled analyses of Os in association with high aFaP1-as1, anril, casc15, ccaT2, gaPlinc and h19 expression levels. Note: Weights are from random-effects analysis. Abbreviations: aFaP1-as1, aFaP1 antisense rna 1; anril, cDKn2B antisense rna 1; casc15, cancer susceptibility 15; ccaT2, colon cancer associated transcript 2; gaPlinc, gastric adenocarcinoma associated, positive cD44 regulator, long intergenic noncoding rna; h19, h19, imprinted maternally expressed transcript. Os, overall survival.
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gao et al and new treatment methods. Therefore, novel biomarkers that can improve the prognosis of GC patients are in need. Recently, there is an increasing evidence that lncRNAs can hinder the growth and metastasis of cancer. For example, Xu et al 123 reported that upregulating long stress-induced noncoding 5 (LSINCT5) significantly promoted the growth of the GC cell, while downregulating LSINCT5 suppressed its growth. Dan et al 124 conducted the cancer model experiments using mice, proving that MEG3 overexpression could suppress GC growth and metastasis in vivo by suppressing miR-21 expression. More importantly, several abnormally expressed lncRNAs have been discovered to touch upon the development of GC and perhaps possess prognostic potency in this illness. In view of the above consequences, we conducted this metaanalysis about the prognostic value of lncRNAs in GC.
Research finding
In the present research, a total of 51 articles reporting 19 lncRNAs, which were latent prognostic biomarkers and 
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Prognostic value of lncrnas in gastric cancer 6,095 GC patients were included, among which 18 lncRNAs (except SPRY4 intronic transcript 1 [SPRY4-IT1]) manifested a significantly prognostic value. Meanwhile, strong heterogeneity was only shown in two (H19 and SPRY4-IT1) analyses about lncRNAs, during which there was no significant associations between SPRY4-IT1 expression and OS. Further analysis suggested that AFAP1-AS1, CCAT2, LINC00673, PANDAR, PVT1, Sox2ot, ZEB1-AS1 and ZFAS1 were strong candidates in predicting prognosis of GC patients. Figure 8 shows the summary of lncRNAs with aberrant expression, potential targets and pathways included in this study. It is noteworthy that there existed inconsistent outcomes about expression of HOTTIP and SPRY4-IT1 compared with normal controls, so these two lncRNAs were not shown to be up or down expressed. Unexpected results were findings that CDKN1A was target of both CASC15 and PANDAR and KLF2 was target of both LINC00673 and ZFAS1. In addition, cell proliferation was the most related cell function of these lncRNAs.
Molecular mechanisms
Merits
The current study had several merits: 1) nearly all articles appraising the associations between OS of GC patients and lncRNA expression were searched and are clearly shown in Table 1 ; 2) most of our meta-analyses revealed no or low heterogeneity (I 2 #50.0%), indicating relatively consistent results of the meta-analyses and 3) all the included studies had a relatively large sample size ($30), decreasing the error of low sample size to some degree. limitations However, the limitations of this work could not be ignored: 1) only English papers were included in the present research, which may exclude potentially relevant articles; 2) most of the patients were from China, which cannot adequately represent the prognosis of global patients; 3) only the metaanalysis of HOTAIR was composed of nine articles, [41] [42] [43] [44] [45] [46] [47] [48] [49] and other merged analyses about lncRNAs were from relatively small article number (two to four) and 4) the papers omitted due to no mention of OS may provide a lot of information on which lncRNAs hold promise for a prognostic value.
inspirations
This study left several inspirations for us: 1) lncRNAs were arranged in an alphabetical order as shown in Table 1 , via which the recently research frequency could be distinctly seen by clinical workers and scientific researchers; 2) the detailed outcomes of OS from the pooled analyses are shown in Table 3 , through which combined detection of lncRNAs might better predict the survival time of GC patients and 3) for the molecular mechanisms of the included lncRNAs, their connections are shown in Figure 8 , which might play enlightening roles in future basic experiments on lncRNAs in GC.
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Conclusion
This meta-analysis suggested that the abnormally expressed lncRNAs (AFAP1-AS1, ANRIL, CASC15, CCAT2, GAPLINC, H19, HOTAIR, HOTTIP, LINC00673, MALAT1, MEG3, PANDAR, PVT1, Sox2ot, UCA1, XIST, ZEB1-AS1 and ZFAS1) were significantly associated with the survival of GC patients, among which AFAP1-AS1, CCAT2, LINC00673, PANDAR, PVT1, Sox2ot, ZEB1-AS1 and ZFAS1 were strong candidates in predicting prognosis of GC patients.
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